AHAbdullah Husain

Abdullah Husain

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Abdullah Husain has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prospective analysis on the outcomes of histotripsy for primary and metastatic liver tumors

    by Albert C.Y. Chan, Vince W.H. Lau, Gordon T.C. Wong, Yau W. Chan, Kwan Man, Lau Y. Ng, Huanhuan Ma, Abdullah Husain, Irene O.L. Ng

    Background: Histotripsy is an innovative, non-invasive ultrasound-based technology that mechanically disrupts liver tumor tissues at the cellular level through acoustic cavitation. It offered precise tissue destruction with minimal collateral damage. This study evaluated the safety and efficacy of this novel treatment through clinical and biomolecular analysis. Methods: From August to 30 December 2024 patients with malignant liver cancers, Child-Pugh A liver function, and tumors <10 cm were recruited. Treatments were performed under general anesthesia using histotripsy with tailored approaches for left and right liver tumors. Technical success and treatment efficacy were assessed by contrast-enhanced MRI at 36 hours and 1 month post-procedure. Complications were classified by Clavien-Dindo criteria. Plasma cytokine profiles were analyzed pre-treatment, at 1-day, and 1-month post-treatment. A cytokine score predictive of clinical outcomes was derived via Least Absolute Shrinkage and Selection Operator regression and Receiver Operating Characteristic analysis. Results: A total of 19 patients (63.3%) had hepatocellular carcinoma while the remaining 11 patients had liver metastases from different origins including colorectal, pancreas, breast, and thyroid. A total of sixty tumors with a median tumor diameter of 1.8 cm and a median tumor number per patient of 2 were treated. The 36-hour technical success rate was 95% and 1-month efficacy rate was 82.5%. Procedure-related complications were mild, including transient fever and abdominal discomfort controlled by analgesics; no grade III or above complications occurred. Cytokine profiling revealed a significant systemic inflammatory response at 1-day post-treatment, notably increased Interleukin 6 (IL-6). A four-cytokine panel (IL-7, IL-6, IL-1α, CXCL1) generated a cytokine score that strongly predicted complete tumor response (area under the curve = 0.955). Higher cytokine scores correlated with greater treatment volume and elevated liver enzymes indicative of an immunomodulatory effect. Conclusion: Histotripsy was a safe and effective non-invasive treatment for liver tumors, demonstrating promising clinical outcomes and systemic immune activation. These findings supported further investigation into its long-term efficacy and potential synergy with immunotherapy.


  • Open Access

    Disparity landscapes of viral-induced structural variations in HCC: Mechanistic characterization and functional implications

    by Xueying Lyu, Karen Man-Fong Sze, Joyce Man-Fong Lee, Abdullah Husain, Lu Tian, Sandrine Imbeaud, Jessica Zucman-Rossi, Irene Oi-Lin Ng, Daniel Wai-Hung Ho

    Oncoviruses can integrate into the host genome and cause tumorigenesis. In particular, hepatitis B virus (HBV) infection accounts for more than 50% of hepatocellular carcinoma (HCC) worldwide. We revealed the global geographical disparity of HBV integration that the landscape of HBV integration between HCC tumor and non-tumorous liver varied in regional cohorts, suggesting the different degrees of clonal enrichment. Most HBV integrations were positionally enriched at telomeres and centromeres (T&C) and they highlighted the novel co-involvement of HBV integration, which likely introduces genomic instability in HCC development. This was confirmed by phospho-H2AX staining. We constructed a large meta-cohort of multiple ethnicities to refine the landscape of HBV integration. This enables the gene set/family level exploration. As TERT is the most frequently integrated gene, we further investigated the underlying mechanistic modulation of TERT transcription activation and revealed the concurrent influence by the orientation and relative distance of HBV integration. Additionally, clonal disparity of HBV integration was observed among patients and the higher level of clonal disparity score can indicate poor patients’ prognostication. Taken together, our study uncovered the different levels of clonal enrichment of HBV integration, mechanistic insights, and prognostic biomarker signature, to strengthen our understanding in HBV-associated hepatocarcinogenesis. Export


  • Open Access

    Midline 1 interacting protein 1 promotes cancer metastasis through FOS-like 1-mediated matrix metalloproteinase 9 signaling in HCC

    by Yung-Tuen Chiu, Abdullah Husain, Karen Man-Fong Sze, Daniel Wai-Hung Ho, Eliana Mary Senires Suarez, Xia Wang, Eva Lee, Hoi-Tang Ma, Joyce Man-Fong Lee, Lo-Kong Chan, et al.

    Background and Aims: Understanding the mechanisms of HCC progression and metastasis is crucial to improve early diagnosis and treatment. This study aimed to identify key molecular targets involved in HCC metastasis. Approach and Results: Using whole-transcriptome sequencing of patients’ HCCs, we identified and validated midline 1 interacting protein 1 (MID1IP1) as one of the most significantly upregulated genes in metastatic HCCs, suggesting its potential role in HCC metastasis. Clinicopathological correlation demonstrated that MID1IP1 upregulation significantly correlated with more aggressive tumor phenotypes and poorer patient overall survival rates. Functionally, overexpression of MID1IP1 significantly promoted the migratory and invasive abilities and enhanced the sphere-forming ability and expression of cancer stemness-related genes of HCC cells, whereas its stable knockdown abrogated these effects. Perturbation of MID1IP1 led to significant tumor shrinkage and reduced pulmonary metastases in an orthotopic liver injection mouse model and reduced pulmonary metastases in a tail-vein injection model in vivo. Mechanistically, SP1 transcriptional factor was found to be an upstream driver of MID1IP1 transcription. Furthermore, transcriptomic sequencing on MID1IP1-overexpressing HCC cells identified FOS-like 1 (FRA1) as a critical downstream mediator of MID1IP1. MID1IP1 upregulated FRA1 to subsequently promote its transcriptional activity and extracellular matrix degradation activity of matrix metalloproteinase MMP9, while knockdown of FRA1 effectively abolished the MID1IP1-induced migratory and invasive abilities. Conclusions: Our study identified MID1IP1 as a regulator in promoting FRA1-mediated-MMP9 signaling and demonstrated its role in HCC metastasis. Targeting MID1IP1-mediated FRA1 pathway may serve as a potential therapeutic strategy against HCC progression.